Navigation menu Search
  • Home
  • About
  • CEME Facts CEME Facts
    • What is CEME?
    • How does CEME work?
    • Why is CEME valuable?
  • Results Results
    • Clients & Testimonials
    • Case studies
  • News
  • Contact
  • Back to top

McCormack Pharma


Call on :

  • New teachings mean new life
  • New teachings mean new directions
  • New teachings mean new IP
  • New teachings mean new methods
  • New teachings mean new sales

McCormack Pharma’s landmark discovery could mean new guidelines for use of anti-platelet drug

1st May, 2015

Using customized relational databases with the capacity to rapidly mine data and identify previously-unknown relationships, McCormack Pharma identifies free fatty acids as the final arbiter in determining the magnitude of clopidogrel resistance.

Download this press release

  • McCormack Pharma’s landmark discovery could mean new guidelines for use of anti-platelet drug

This press release has been distributed to:

  • PR Newswire
  • Previous press release
  • Next press release

Site snapshot

Case studies

  1. Azapropazone (A H Robins; Wyeth)
  2. Clopidogrel (GSK)
  3. Captopril (GSK)
  4. Ketoprofen (Rhone-Poulenc Rorer (RPR))
  5. Buprenorphine (Reckitt & Colman )
  6. View all

News articles

  1. CEME: When a drug’s intracellular footprint doesn’t add up
  2. Dexrazoxane — a smart drug that breaks all the rules
  3. CEME – a purpose-built tool for value-differentiation
  4. CEME - fidelity and precision in gathering and sorting real world data
  5. 40 year-old drug may be preferred choice for post-acute myocardial infarction patients
  6. View all

Press releases

  1. The Deterministic Quasi-Chaos Of Pharma’s Big Data: Me-too drugs and the butterfly effect
  2. McCormack Pharma’s landmark discovery could mean new guidelines for use of anti-platelet drug
  3. McCormack Pharma announces a breakthrough discovery in the mechanism of clopidogrel resistance
  4. View all

Testimonials

  1. Clinigen Group plc
  2. Nycomed
  3. GlaxoSmithKline plc
  4. Javelin Pharmaceuticals
  5. Eisai Europe Ltd
  6. View all

© 2014-2025 McCormack Limited

McCormack Pharma is a trading name of McCormack Limited

Information regarding cookies & data privacy

Web design by Rick Lecoat

  • Home
  • About
  • CEME Facts CEME Facts
    • What is CEME?
    • How does CEME work?
    • Why is CEME valuable?
  • Results Results
    • Clients & Testimonials
    • Case studies
  • News
  • Contact
  • Back to top